Physician profile
Monica Huyentran Lieu
NPI 1184225377
$4,782.61
in general payments reported to CMS, 2019-2025
28 companies · $4,466 in 2025
The $4,466 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $68.28 · 2023: $178 · 2024: $70.84 · 2025: $4,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,714.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $609.58 | 2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $547.32 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $489.71 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $383.85 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $359.63 | 2025 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $329.45 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $316.28 | 2025 | Cobenfy |
| Alkermes, INC. | $251.88 | 2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $222.12 | 2025 | Auvelity, Sunosi |
| Noven Therapeutics, LLC | $164.15 | 2025 | Xelstrym |
| Biogen, INC. | $160.83 | 2025 | Zurzuvae |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.23 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $135.96 | 2025 | Trintellix |
| Lundbeck LLC | $135.24 | 2025 | Rexulti |
| Corium, LLC | $113.92 | 2025 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $51.35 | 2023-2024 | Mounjaro, Zepbound |
| Braeburn INC. | $50.64 | 2025 | Brixadi |
| Indivior INC. | $39.56 | 2025 | Sublocade |
| Amgen INC. | $37.46 | 2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $37.24 | 2022-2023 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $36.99 | 2023 | Quviviq |
| Novo Nordisk INC | $31.39 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.85 | 2022 | |
| Bausch Health US, LLC | $22.92 | 2025 | Aplenzin |
| Hologic Sales and Service, LLC | $20.96 | 2023 | Aptima |
| Luye Pharma (USA) Ltd. | $18.06 | 2025 | Erzofri Extended-Release |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.02 | 2024 | Jardiance |
| Tris Pharma INC | $15.02 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Lieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.